Pharmacokinetics of ADS-5102 (Amantadine) Extended Release Capsules Administered Once Daily at Bedtime for the Treatment of Dyskinesia

BACKGROUND: Preclinical and clinical studies suggest amantadine immediate-release (IR) may reduce dyskinesia in Parkinson’s disease (PD), although higher doses are associated with increased CNS adverse events (AEs). ADS-5102 is an extended release amantadine capsule formulation, designed for once-da...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Clin Pharmacokinet
Autores principales: Hauser, Robert A., Pahwa, Rajesh, Wargin, William A., Souza-Prien, Cindy J., McClure, Natalie, Johnson, Reed, Nguyen, Jack T., Patni, Rajiv, Went, Gregory T.
Formato: Artigo
Lenguaje:Inglês
Publicado: Springer International Publishing 2018
Materias:
Original Research Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6325984/
https://ncbi.nlm.nih.gov/pubmed/29777529
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40262-018-0663-4
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares